真实世界转移性去势抵抗性前列腺癌患者中阿比特龙及其代谢物的暴露-反应分析
多因素分析显示Cmin≥8.4 ng/mL与更长的PSA独立无进展生存期相关(16.9 vs 6.1个月;p=0.033),风险比为0.44(95%CI:0.23-0.82,p=0.01)。活性代谢物D4A的Cmin与疗效无关。
要点
- 42%的真实世界mCRPC患者阿比特龙暴露不足(Cmin≤8.4 ng/mL)。
- 阿比特龙Cmin≥8.4 ng/mL与更长的PSA独立无进展生存期相关。
- 监测阿比特龙Cmin有助于识别治疗次优风险患者。
核心结论
- mCRPC患者阿比特龙Cmin≥8.4 ng/mL者预后优于低Cmin者。
- 监测阿比特龙Cmin可识别治疗次优风险患者,可能适合优化治疗。
研究设计与样本
- 采用经验证的液相色谱-质谱法分析阿比特龙及其代谢物水平。
- 使用计算得到的阿比特龙及活性代谢物Δ(4)-阿比特龙(D4A)的Cmin值进行单变量和多变量Cox回归分析。
主要发现
- 42%患者暴露不足(平均阿比特龙Cmin≤8.4 ng/mL)。
- 多变量分析中,Cmin≥8.4 ng/mL与更长的PSA独立无进展生存期相关(16.9 vs 6.1个月;p=0.033)。
- Cmin≥8.4 ng/mL的风险比为0.44(95%CI:0.23-0.82,p=0.01)。
- D4A Cmin与治疗疗效无关系。
关键数值与推荐
- 阿比特龙目标Cmin为8.4 ng/mL。
- Cmin≥8.4 ng/mL与PSA独立无进展生存期16.9个月相关,低于此值为6.1个月(p=0.033)。
临床怎么用
- 在真实世界mCRPC患者中监测阿比特龙Cmin,识别暴露不足者。
- 对Cmin≤8.4 ng/mL的患者考虑治疗优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Abiraterone acetate is an oral 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor approved for the treatment of metastatic castration-resistant prostate cancer (mCPRC) patients. Previously, a prospective observational trial demonstrated a relationship between abiraterone trough concentrations (Cmin) in plasma and treatment efficacy. The aim of our study was to investigate the exposure-response relationship of abiraterone and its metabolites, and to study if the proposed target for abiraterone of 8.4 ng/mL is feasible in a "real-world" patient cohort. PATIENTS AND METHODS: mCRPC patients who had at least one abiraterone plasma concentration at steady-state were included in this study. Plasma abiraterone and its metabolites levels were analyzed using a validated liquid chromatography-mass spectrometry method. Using calculated Cmin values of abiraterone and its active metabolite Δ(4)-abiraterone (D4A), univariate, and multivariable Cox regression analyses were performed. RESULTS: Sixty-two patients were included in this retrospective analysis, of which 42% were underexposed (mean abiraterone Cmin ≤ 8.4 ng/mL). In multivariable analysis, Cmin ≥ 8.4 ng/mL was associated with longer prostate-specific antigen (PSA) independent progression-free survival (16.9 vs 6.1 months; p = 0.033), which resulted in a hazard ratio of 0.44 (95% confidence interval: 0.23-0.82, p = 0.01). D4A Cmin did not show a relationship with treatment efficacy. CONCLUSION: Our study shows that mCRPC patients with an abiraterone Cmin ≥ 8.4 ng/mL have a better prognosis compared with patients with low Cmin. Monitoring Cmin of abiraterone can help to identify those patients at risk of suboptimal treatment for whom treatment optimization may be appropriate.
引用
- van Nuland M, Groenland SL, Bergman AM, et al. Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019. PMID: 31611636. doi:10.1038/s41391-019-0179-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。